Clinical Trial Goal
To find out if low-dose decitabine and venetoclax is safe and works well to treat AML or MDS
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML or MDS
- Do not have acute promyelocytic leukemia
- Have not been treated with any of the following:
- Azacitidine
- Decitabine
- Venetoclax
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Decitabine is a drug that blocks the growth of cancer cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Decitabine – Given as a shot under your skin. The dose you'll get depends on when you start the trial and how safe it has been
- Venetoclax – A pill that you take by mouth 1 time each week
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat MDS or AML is new and unproven.
Locations
University of California Davis Health (UC Davis Health)RECRUITING
Sacramento, California
Montefiore Medical CenterRECRUITING
The Bronx, New York
Mendel Goldfinger, MD, 718-920-4257
White Plains HospitalRECRUITING
White Plains, New York
Sponsors
collaborator: The V Foundation for Cancer Research, collaborator: Icahn School of Medicine at Mount Sinai, collaborator: Servier, lead: Montefiore Medical Center
